Your browser doesn't support javascript.
The role of T-cell immunity in COVID-19 severity amongst people living with type II diabetes.
Tong, Zhen Wei Marcus; Grant, Emma; Gras, Stephanie; Wu, Melanie; Smith, Corey; Barrett, Helen L; Gallo, Linda A; Short, Kirsty R.
  • Tong ZWM; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.
  • Grant E; La Trobe University - La Trobe Institute for Molecular Science (LIMS), Melbourne, Australia.
  • Gras S; Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia.
  • Wu M; La Trobe University - La Trobe Institute for Molecular Science (LIMS), Melbourne, Australia.
  • Smith C; Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia.
  • Barrett HL; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.
  • Gallo LA; QIMR Berghofer Medical Research Institute - QIMR Berghofer Centre for Immunotherapy and Vaccine Development Brisbane, Australia.
  • Short KR; Department of Endocrinology, Mater Health, Brisbane, Australia.
FEBS J ; 288(17): 5042-5054, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1295003
ABSTRACT
The COVID-19 pandemic has highlighted the vulnerability of people with diabetes mellitus (DM) to respiratory viral infections. Despite the short history of COVID-19, various studies have shown that patients with DM are more likely to have increased hospitalisation and mortality rates as compared to patients without. At present, the mechanisms underlying this susceptibility are unclear. However, prior studies show that the course of COVID-19 disease is linked to the efficacy of the host's T-cell responses. Healthy individuals who can elicit a robust T-cell response are more likely to limit the severity of COVID-19. Here, we investigate the hypothesis that an impaired T-cell response in patients with type 2 diabetes mellitus (T2DM) drives the severity of COVID-19 in this patient population. While there is currently a limited amount of information that specifically addresses T-cell responses in COVID-19 patients with T2DM, there is a wealth of evidence from other infectious diseases that T-cell immunity is impaired in patients with T2DM. The reasons for this are likely multifactorial, including the presence of hyperglycaemia, glycaemic variability and metformin use. This review emphasises the need for further research into T-cell responses of COVID-19 patients with T2DM in order to better inform our response to COVID-19 and future disease outbreaks.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / Diabetes Mellitus, Type 2 / COVID-19 / Hyperglycemia Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: FEBS J Journal subject: Biochemistry Year: 2021 Document Type: Article Affiliation country: Febs.16105

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: T-Lymphocytes / Diabetes Mellitus, Type 2 / COVID-19 / Hyperglycemia Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: FEBS J Journal subject: Biochemistry Year: 2021 Document Type: Article Affiliation country: Febs.16105